Log In
BCIQ
Print this Print this
 

tremelimumab (CP-675, CP-675,206, CP-675206)

Also known as: formerly ticilimumab

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionHuman mAb against cytotoxic T-lymphocyte associated protein 4 (CTLA4; CD152)
Molecular Target Cytotoxic T-lymphocyte associated protein 4 (CTLA4) (CD152)
Mechanism of ActionCTLA-4 (CD152) antagonist; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

5

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today